- Home
- Equipment
- north america
- preclinical data
Refine by
Preclinical Data Equipment Supplied In North America
32 equipment items found
Manufactured by:Virpax Pharmaceuticals based inBerwyn, PENNSYLVANIA (USA)
Kappa and delta opioid agonists have been shown to provide analgesic benefit while sparing mu agonist toxicity1. Preclinical data supports analgesia from enkephalin without significant opioid tolerance or drug liking. Typically, exogenous enkephalins are rapidly degraded and have difficulty accessing the CNS2. Using a novel encapsulation method known as Molecular ...
by:Enveric Biosciences, Inc. based inNaples, FLORIDA (USA)
Enveric Biosciences seeks to advance novel combinations of CBD with chemotherapeutic agents and immunotherapies. Preclinical data suggests combination therapies may improve the activity of certain chemotherapies or cancer immunotherapies, potentially enabling more potent or longer-lasting therapeutic effects. In addition, combination therapies may allow for the ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
What differentiates this therapy from our ADP-A2M4 SPEAR T-cells is that these cells also express the CD8α co-receptor alongside the engineered TCR that targets MAGE-A4. Preclinical data indicate that co-expression of CD8α may broaden the immune response against solid tumors and increase anti-tumor activity by leveraging CD4+ cells into CD8+ killer or ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
Stimulator of Interferon Genes (STING) is a well-studied innate immune pathway capable of inducing anti-tumor immune activity. Our preclinical data show that the anti-tumor activity of Immunosynthen STING-agonist ADCs involves the targeted activation of the STING pathway in both tumor-resident immune cells and in tumor cells, in an antigen binding-dependent ...
Manufactured by:Brooklyn ImmunoTherapeutics (BTX) based inSan Diego, CALIFORNIA (USA)
Cytokine production induced by PHA mimics that seen after brisk stimulation of human immune cells by an immunogenic pathogen or an infection. We obtain source material PBMCs from FDA-licensed blood banks. Preclinical data from animal and in vitro studies, as well as biologic data from patients in clinical trials, demonstrate that IRX-2 acts in ...
Distributed by:LT Scientific, Inc. based inCarson City, NEVADA (USA)
The Agilent Discovery MR901 System provides a high quality and robust pre-clinical MRI research environment operated via a powerful and intuitive GE clinical user interface. Produced in association with GE Healthcare the Discovery MR901 System is optimized for pre-clinical imaging at 7T enabling not only straightforward operation by clinical-familiar staff, but simple and relevant comparison of ...
Manufactured by:ASC Therapeutics based inMilpitas, CALIFORNIA (USA)
Stem cells, including inducible pluripotent stem cells, mesenchymal stem cells (MSCs) and other primary pluripotent cells, hold the potential to treat a variety of diseases. We are currently focusing on developing an allogeneic decidua stromal cells (DSCs)-based platform to treat severe immune-mediated diseases. Our pre-clinical and clinical data suggest that the immunomodulatory activity of DSCs ...
Manufactured by:AVEO Pharmaceuticals, Inc. based inBoston, MASSACHUSETTS (USA)
AV-203 (CAN017) is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian and pancreatic ...
by:Hookipa Pharma Inc. based inVienna, AUSTRIA
Our scientific platform includes two distinct approaches to arenavirus-based therapies: replicating and non-replicating. Our replicating technology is designed to create a stronger immune response that we believe is more appropriate for use in oncology. Our non-replicating technology is designed to evoke a potent immune response for prophylactic use against infectious disease. ...
by:Cyrus Biotechnology Inc. based inSeattle, WASHINGTON (USA)
Novel IL-2 approaches and technologies are driving innovation in the therapeutic development space. The IL-2 pathway influences critical aspects of both immune stimulation and immune regulation, through the development and expansion of regulatory T cells ...
Manufactured by:Immune-Onc Therapeutics, Inc. based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is evaluating IO-108, an antagonist antibody targeting the myeloid checkpoint, LILRB2 (also known as ILT4). The U.S. FDA has cleared the IND application for IO-108 as a potential therapy for solid tumors. The company expects to begin clinical trials with IO-108 in the second half of ...
Manufactured by:Sanara MedTech Inc. based inFort Worth, TEXAS (USA)
FORTIFY TRG Tissue Repair Graft is a 100% porcine small intestinal submucosa (SIS) ECM intended for implantation to reinforce soft ...
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
IVX-411 targets SARS-CoV-2, the coronavirus that causes COVID-19. Developed using cutting-edge structure-based design techniques at the Institute for Protein Design at the UW School of Medicine, IVX-411, our lead vaccine candidate for COVID-19, is a self-assembling protein nanoparticle that displays 60 copies of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain (RBD) in a highly ...
Manufactured by:Meissa Vaccines, Inc. based inRedwood City, CALIFORNIA (USA)
Meissa is developing a live attenuated COVID-19 vaccine candidate, MV-014-212, to induce mucosal and systemic immunity and protect against SARS-CoV-2, the novel coronavirus that causes COVID-19. Like Meissa’s RSV vaccine candidate, MV-014-212 offers significant potential advantages for global deployment, including needle-free intranasal administration, a single adjuvant-free dose to induce ...
Manufactured by:AVEO Pharmaceuticals, Inc. based inBoston, MASSACHUSETTS (USA)
AV-380 is AVEO’s first-in-class, potent, humanized inhibitory IgG1 antibody targeting growth differentiation factor 15 (GDF15). GDF15 is a pro-inflammatory cytokine whose elevated circulating levels have been correlated with cachexia in cachectic cancer patients and several animal models of cancer cachexia. Current evidence suggests that a pro-inflammatory state may be responsible for many ...
Manufactured by:Cancer Targeted Technology based inWoodinville, WASHINGTON (USA)
CTT’s lead therapeutic product, CTT1403, is a PSMA-targeted 177Lu-labeled agent for prostate cancer that can has superior binding characteristics, long circulation half-life, enhanced tumor uptake and unparalleled anti-tumor efficacy. CTT1403 will specifically deliver the radionuclide, 177Lu, minimizing toxic side effects and more effectively treating metastatic prostate cancer and other ...
Manufactured by:Orchestra BioMed, Inc. based inNew Hope, PENNSYLVANIA (USA)
BackBeat CNT™ is a patented bioelectronic treatment for hypertension that is designed to drive an immediate, substantial and persistent reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain lowered blood pressure long-term. A patented, intelligent bioelectronic treatment for hypertension. BackBeat Cardiac Neuromodulation Therapy is ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
ADCs are not one-size-fits-all. The Dolasynthen platform enables an iterative approach to develop the right ADC for a given indication through customization and optimization. Dolasynthen utilizes a synthetic scaffold for precise control of DAR (from 2-24) and site-specific antibody bioconjugation. The platform is also able to homogeneously generate ADCs with precisely defined DARs for consistent ...
Manufactured by:Elpiscience based inShanghai, CHINA
ES104 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization. VEGF also plays an important role in creating an immune suppressive TME. Pre-clinical and early clinical data of ES104 show that blocking both pathways provides robust ...
Manufactured by:Lung Therapeutics, Inc. based inAustin, TEXAS (USA)
A pleural effusion is defined by the build-up of fluid in the pleural cavity, predominantly resulting from pneumonia. A loculated pleural effusion (LPE) occurs when scar tissue forms in the pleural cavity, trapping the fluid and preventing drainage. Our lead compound, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue. We believe ...